physically removes the AVM. Nevertheless, depending on factors such as lesion location, size, and flow, the morbidity and mortality rates associated with microsurgical removal stay relatively high.
Stereotactic radiosurgery is a minimally invasive therapy aimed at achieving a radiological outcome of complete nidus obliteration and the disappearance of early draining vein(s), which corresponds to a reduction in the hemorrhage risk back to that of the general population. 6 We report our 25-year experience in treating pediatric AVM and review the radiosurgical strategy, outcome, and side effects. This study, to the best of our knowledge, represents the largest series of pediatric patients with radiosurgically treated AVMs thus far described in the neurosurgical literature.
Methods
The cohort was selected from a prospectively maintained departmental database, selecting for the age group up to and including 16 years of age at treatment. Further clinical data were obtained from the case notes of each patient. Telephone interviews were conducted with clinicians and family doctors to complete the data.
Statistical analysis was performed in the R program using the appropriate tests: Pearson product-moment correlation coefficient, phi correlation coefficient, and Cox proportional hazards for multivariate analysis.
Results
Focused radiation was stereotactically delivered using an early prototype Gamma Knife (Nucletec SA) up to 2000 and an Elekta Gamma Knife (models C and 4C) after 2000. The procedural protocol has been described elsewhere. 3, 4 As a rule, we induce general anesthesia in patients under 14 years of age and in selected cases of older patients. Two hundred thirty-nine procedures (58%) were performed with the patient under general anesthesia.
Among 10,682 patients treated with GKS at our institution , 410 treatments were performed in 363 children with AVMs. Forty-three of these children were retreated subsequent to an initial partial response (nidus reduction). Complete follow-up data were available for 220 patients (40 retreated patients). Of the remaining 143 patients, 139 received treatment in the past 3.5 years, too short a period (from a radiosurgical perspective) to ascertain a definitive result, and 4 had no radiological follow-up. In the following analysis, obliteration data refer to the 220 cases, while all other aspects, including complications, refer to the whole cohort.
The mean age was 12 ± 3.22 years (mean ± SD), with a range from 1 to 16 years; excluding a 1-year-old child made for a range of 4-16 years (Fig. 1 left) . Sixteen percent of the patients had previously undergone embolization procedures. Hemorrhage was by far the most common presentation (80.2%), followed by seizures (8.3%) and persistent migrainous headaches (6.3%). Overall seizure prevalence in the treated population was 19.9%. Other presenting symptoms included visual disturbances (blurred vision and diplopia) in 1.1%, dysphasia in 1.1%, and nausea and vomiting in 0.8% (Table 1 ). The frontal lobes were the most common AVM location, followed closely by the parietal lobes; the internal capsule was the least common. The mean lesion volume was 3.75 ± 5.3 cm 3 (range 0.01-32.8 cm 3
; Fig. 1 right) and the median was 1.57 cm 3 . The median SM grade was III (range I-V), with the following distribution: Grade I, 6%; Grade II, 27%; Grade III, 48%; Grade IV, 18%; and Grade V, 2%. The mean peripheral (therapeutic) radiation dose was 22.7 ± 2.3 Gy (15-25 Gy), using the 50% isodose (range 48%-60%). The mean maximum delivered dose was 43.6 ± 6 Gy (range 25-51.4 Gy). Radiation was delivered using an average of 4.4 ± 3.1 fields (range 1-18 fields). The most widely used collimator was the 8-mm one (50.4% of the total number of shots), and the least used was the 18-mm one (5.6%).
Recently, 4 patients had preplanned staged treatments because of the size of their lesions (> 15 cm 3 ). Each of these patients received 2 treatments with a peripheral dose of 17.5 Gy, 3 months apart, and follow-up results are not yet available.
Regarding radiological follow-up, in our current protocol we perform noninvasive tests-MRI and magnetic resonance digital subtraction angiography-2 years after treatment. 5 If no residual abnormality is demonstrated, a catheter angiography is performed immediately for confirmation. If MRI suggests a persisting nidus, catheter angiography is delayed until 3-4 years after treatment. If an abnormality is still visible at that point and there is an obvious reduction in nidus size, patients are offered further radiosurgical treatment at around 4 years after the first treatment. To monitor new events and side effects, we recommend routine clinical follow-up every 6 months until obliteration in uncomplicated cases. Once the AVM is obliterated, patients have an open-ended follow-up with their local consultants, who inform us of any delayed complications.
The obliteration rate after a single procedure was 71.3% (calculated in the 220 cases with sufficient and complete follow-up data) and for repeat treatments was 62.5%, yielding an overall obliteration rate of 82.7%. Oblit eration was radiologically defined as complete disappearance of the nidus and early draining vein(s). The mean time to radiological confirmation of obliteration was 32.4 ± 20.8 months for 1-time treatments and 79.6 ± 34.2 months for repeat treatments (considered from the first radiosurgery procedure). The overall complication rate (calculated based on the entire cohort of 363 patients) was 3.6%, with radionecrosis (1.1%) and new motor deficit (0.8%) being the most common complications (Table  2 ). There were no new cranial nerve palsies or sensory deficits. There was a 2.2% cumulative risk of bleeding in the "therapeutic window" between radiosurgery and obliteration.
There was a somewhat surprising lack of correlation between outcome (defined as yes/no in terms of complete obliteration; based on 220 patients) and radiosurgical dose when the peripheral (therapeutic) dose was between 20 and 25 Gy, possibly because this range was relatively narrow. We mainly use 3 discrete doses, always aiming for 25 Gy and reducing the dose by 10% or 20% based on considerations such as lesion size and area of eloquent brain involved, thus yielding doses of 22.5 and 20 Gy, respectively. Only 4 patients in the whole cohort received a peripheral dose below 20 Gy: 3 patients received 18, 16, and 15 Gy, respectively, and the AVMs were obliterated; and 1 patient received 17.5 Gy, and the AVM was not obliterated. Three patients received a peripheral dose of 22 Gy, and they all had positive results. Excluding those aforementioned 7 patients, all other patients (213) received 25 Gy (43.2% of patients), 22.5 (32.7%), or 20 Gy (20.9%). Obliteration percentages by peripheral dose were 86.31% for 25 Gy, 77.77% for 22.5 Gy, and 82.6% for 20 Gy, making outcome statistically independent of dose to the margin (p = 0.43). The same held true for the maximum dose in each of the dose plans (p = 0.54).
Neither did outcome correlate statistically significantly with other parameters, that is, patient age (p = 0.06), lesion volume (p = 0.48), SM grade (p = 0.63), and angioarchitecture (defined as diffuse, intermediate, or compact; p = 0.64).
The time to obliteration did not differ significantly among the 3 peripheral doses (p = 0.35; Fig. 2) . As with outcome analysis, no correlation was found between the time to obliteration and other parameters tested (patient age, lesion volume, peripheral and maximal radiation doses, and SM grade). Trends of correlation between time to obliteration and number of arterial feeders (p = 0.1) and angioarchitecture (p = 0.08) did not reach statistical significance.
Discussion
Active management of childhood AVM is essential because the annual bleeding risk of 2%-4% accrues over time, resulting in an unacceptable lifetime risk of hemorrhage, which could lead to severe neurological deficits or death. Successful treatment may involve resection, embolization, stereotactic radiosurgery, or a combination of these modalities. For an easily accessible (superficial) AVM in a noneloquent area, microsurgery remains a valid approach and probably becomes the gold standard if the aforementioned criteria are completed by an acute presentation with intracranial hemorrhage. 11 Arteriovenous malformations located in deep and/or eloquent areas, or residual AVMs after subtotal resection and/or partially successful embolization, are best treated with stereotactic radiosurgery, which has been proven to be safe and effective in several studies. 5, 9 Gamma Knife surgery alone is also a valid primary treatment for almost all other AVMs, except in cases in which a combination of factors makes this option less attractive (very large AVMs in an eloquent location or lesions with diffuse angioarchitecture). In general, however, cases that are not fit for radiosurgery present a formidable challenge for other active treatments as well and are usually left with an observation approach.
Obliteration rates in the present study-71.3% for 1-time radiosurgical treatment and 82.7% overall-are in keeping with those in some reported radiosurgery studies and significantly higher than those in other studies; details of previous studies are provided in Table 3. 1,2,10,12, [14] [15] [16] [17] [18] While our complete dose range (15-25 Gy) has been widely used and cited in other studies, we have, to our knowledge, one of the highest mean peripheral doses (22.7 Gy) documented in the pediatric AVM radiosurgery literature.
14 Our statistical analysis showed that outcome was independent of dose, but this finding must be qualified; that is, the majority of our patients (359 [98.9%] of 363) received doses between 20 and 25 Gy so we could not provide comparison with doses outside this range. On the other hand, some of the studies cited above used average peripheral doses below 20 Gy. 12, 16 There is a real possibility that peripheral doses between 20 and 25 Gy may be indifferent to outcome because this range is too narrow to show a difference (although further studies are necessary to ascertain this), while a reduction to a dose below 20 Gy may be deleterious to the final goal (complete obliteration).
Statistical analysis failed to significantly correlate obliteration to other parameters, such as lesion volume, SM grade, patient age, number of arteries feeding the AVM, and angioarchitecture. In contrast to the literature on radiosurgery in the adult population, in which radiation dose, lesion volume, and angioarchitecture (diffuse vs compact nidus) are well-established prognostic factors for response to radiosurgical treatment, the scant pediatric literature reveals few such correlations. One study reporting a 47% obliteration rate for a 20-Gy mean margin dose showed that a diffuse nidus and low peripheral dose were associated with an incomplete response. 18 Other studies inversely correlated outcome with AVM size, 7, 12 while still another suggested a better response for children younger than 10 years of age with a low lesion volume and SM grade.
14 It is usually accepted that the SM grade does not correlate with radiosurgery response in either adult or pediatric cohorts. 13 No parameter is consistently associated with outcome in a reasonable percentage of case series, and most studies, ours included, do not reveal any significant correlations. 1, 16 As regards the identification of prognostic factors, the response to radiosurgery is more unpredictable in the pediatric than in the adult population. The time to obliteration in our study was also independent of other parameters, including peripheral dose (Fig. 2) .
Our cumulative risk of side effects was 3.6% (Table  2) , which is in keeping with rates in the existing literature. Most authors using GKS have reported similar or slightly higher morbidity (for example, 3.2% 17 and 8%
12
), whereas those using LINAC-based radiosurgery reported higher complication rates (for example, 23.5% 8 and 47% 18 ). This difference may be related not only to the platform used to deliver radiation (that is, LINAC vs GKS), but also to a complex combination of factors such as patient selection, quality of dose plans, and center-specific policy of dose adjustment for high-risk lesions.
The overall bleeding rate in the therapeutic window between radiosurgery and obliteration was 2.2% in our study. This rate seems lower than those reported in the literature, for example, 4%, 12 9%, 17 and 25%. 16 The referral, follow-up, and communication systems within the National Health System of the United Kingdom are outstanding, and losing one of these patients to followup would be an extremely unlikely event. We cannot adequately explain this lower posttreatment bleeding risk. Patient selection bias is always a possibility, although we believe we have tackled some formidable treatment challenges along the years, and our center does not easily shy away from treating an AVM unless there is compelling evidence that a treatment carries a risk/benefit ratio that is clearly unacceptable to the patient.
Routine neuropsychological assessment of the treated children, both before and at regular intervals following the procedure, has not been consistently performed. We acknowledge the caveat that radiation may have unpredictable effects on the developing brain, even with a highly focused manner of delivery such as in GKS, which aims to maximize delivery to the lesion while minimizing exposure of surrounding healthy brain. Anecdotally, we have not found significant neurocognitive impairment in children who have received radiosurgical treatment, but this matter certainly deserves more rigorous research in the future. One of the difficulties with such an assessment is the overlap of effects from hemorrhage, epilepsy, anticonvulsant medication, and previous (or subsequent) surgery and embolization with any effects that might arise from radiosurgery.
Conclusions
This pediatric patient series, the largest in the world to the best of our knowledge, reinforces the conclusion that GKS is a safe and effective treatment for pediatric AVM, yielding a high obliteration rate with minimal morbidity and no mortality. Despite its limitations-for example, delayed effect with persistence of the bleeding risk for 2-4 years posttreatment-GKS has established itself as a valid active management option for AVMs in children.
